Influencing the epidermal growth factor receptor - new prospects in the treatment of non-small-cell bronchogenic carcinoma

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

SKŘIČKOVÁ Jana BABIČKOVÁ Lenka

Year of publication 2004
Type Article in Periodical
Magazine / Source Studia Pneumologica et Phthiseologica
MU Faculty or unit

Faculty of Medicine

Citation
Field Pneumology
Keywords non-small-cell bronchogenic carcinomua; oncological therpy; epidermal growth factor receptor (EGFR); EGFR tyrosinekinase inhibitors; gefitinib
Description To influence natural regulatory mechnisms, which control the metabolism, proliferation and migration of tumour cells, biological therapy resorts to low-molecular preparations, macromolecules and cellular immune-type effectors. Today we have primarily information on the influencing of the epidemal growth factor receptor - EGFR.Research concentrates above all on the possibility of inhibiting the intracellular domains of the EGF receptor that has a tyrosinekinase activity. This oncological tratment targes intracellular mechanism of the transfer ot the signal taht calls forth changes in the proliferation activity of tunour cells. In their paper the authors discuss various possibilities of influencing EGFR and their appliction in clinical practice.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.